The short version of NAD+ fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide derivative of nicotinamide |
| Molecular formula | C11H15N2O8P | Free acid form; salts may differ |
| Molar mass | 334.22 g/mol | Approximate value for free acid |
| CAS Registry Number | 1094-61-7 | Common beta isomer |
| Solubility | Water-soluble | Polar molecule; solubility varies with pH and form |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
== External links == Stesam (etifoxine hydrochloride) Summary of Product Characteristics (SPC) Stresam (etifoxine hydrochloride) Patient Leaflet Stresam (etifoxine hydrochloride) Package Insert Etifoxine French Commission Nationale de Pharmacovigilance Review (Original French) Etifoxine French Commission Nationale de Pharmacovigilance Review (English Translation) Etifoxine European Medicines Agency Assessment Report
Salvinorin B ethoxymethyl ether, also known as 2-O-ethoxymethylsalvinorin B (2-EMSB) or as symmetry, is a semi-synthetic analogue of the natural product salvinorin A, the psychoactive chemical in Salvia Divinorum, with a longer duration of action of around 3 hours (compared to less than 30 minutes for salvinorin A), and increased affinity and intrinsic activity at the κ-opioid receptor. Like the related compound herkinorin, 2-EMSB is made from salvinorin B, which is most conveniently made from salvinorin A by deacetylation, as while both salvinorin A and salvinorin B are found in the plant Salvia divinorum, salvinorin A is present in larger quantities. 2-EMSB has an affinity (Ki) of 0.32 nM at the κ-opioid receptor, and around 3,000 times selectivity over the μ- and δ-opioid receptors, making it one of the most potent and selective κ-opioid receptor agonists yet discovered. In animal studies it fully substituted for salvinorin A and the synthetic κ-opioid receptor agonist U-69593, and was active at doses as low as 0.005 mg/kg. Human bioassays found the compound to be active at 50 μg smoked. It has been sold online as an analytical standard.
Reticular (linear) pattern (sometimes called "reticulonodular" because of the appearance of nodules at the intersection of the lines, even though there are no true nodules present) idiopathic pulmonary fibrosis connective tissue disease sarcoidosis radiation fibrosis asbestosis lymphangitis carcinomatosa PCP Nodular pattern
Sources: en.wikipedia.org
Alpha-synuclein has been shown to interact with Dopamine transporter, Parkin (ligase), Phospholipase D1, SNCAIP, Tau protein. Beta amyloid Synuclein Contursi Terme - the village in Italy where a mutation in the α-synuclein gene led to a family history of Parkinson's disease Anti-α-synuclein drug Media related to Alpha-synuclein at Wikimedia Commons alpha-Synuclein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human SNCA genome location and SNCA gene details page in the UCSC Genome Browser.
Technetium-99 (99Tc) is an isotope of technetium that decays with a half-life of 211,000 years to stable ruthenium-99, emitting beta particles, but effectively no gamma rays. It is the most significant long-lived fission product of uranium fission, and the largest single contributor to the long-lived radioactivity of nuclear waste. Technetium-99 has a fission product yield of 6.0507% for thermal neutron fission of uranium-235. The metastable technetium-99m (99mTc) is a short-lived (half-life about 6 hours) nuclear isomer used in nuclear medicine, produced from molybdenum-99. It decays by isomeric transition to technetium-99, a desirable characteristic, since the very long half-life and type of decay of technetium-99 imposes little further radiation burden on the body.
Insulin glargine sold, among others, under the brand name Lantus (manufactured and marketed by Sanofi) is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. It is injected just under the skin. Effects generally begin an hour after use. Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain. Other serious side effects include low blood potassium. NPH insulin rather than insulin glargine is generally preferred in pregnancy. After injection, microcrystals slowly release insulin for about 24 hours. This insulin causes body tissues to absorb glucose from the blood and decreases glucose production by the liver. Insulin glargine was patented, but the patent expired in most jurisdictions in 2014. It was approved for medical use in the United States in 2000. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 30th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product called Semglee (insulin glargine-yfgn) for the treatment of diabetes.
Sources: en.wikipedia.org
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.
NMN is converted to NAD+ by NMNAT enzymes. NAD+ is a coenzyme in redox reactions and a substrate for signaling enzymes. This relationship makes NMN a focus of NAD+ research.
No, NMN and nicotinamide riboside are distinct compounds. Nicotinamide riboside can be phosphorylated to form NMN inside cells. Both are studied as NAD+ precursors.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ metabolism. It occurs naturally in cells and can also be produced synthetically for research or commercial use. Its name reflects its composition: nicotinamide, ribose, and a phosphate group.